

- **Name:** Sandip Patel
 - **Current Position & Affiliation:** Professor, Medical Oncology, UC San Diego
 - **Country:** USA
-

• Educational Background:

BS Duke University
MD Baylor College of Medicine
Internal Medicine Residency UCLA
Hematology/Oncology Fellowship Duke

• Professional Experience:

Professor, Medical Oncology, UC San Diego
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Experimental Therapeutics
Co-Leader, Solid Tumor Therapeutics
Medical Director, Clinical Research Informatics

• Professional Organizations:

ASCO
IASLC
AACR
SITC

• Main Scientific Publications:

1. Olingy C, Alimadad A, Aruaji DJ, Barry D, Gutierrez NA, Werbin MH, Arriola E, **Patel SP**, Ottensmeier CH, Dinh QH, Hedrick CC. CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer. *Frontiers in Immunology*. 14 April 20-22. <https://doi.org/10.3389/fimmu.2022.842653>
2. Javier-DesLoges J, Nelson TJ, Murphy JD...**Patel SP**, Martinez ME, Rose BS. Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials. *Cancer* 2022 (128) 770-777.
3. Bylsma S, Yun K, **Patel SP**, Dennis MJ. Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. *Current Treatment Options in Oncology* (2022). <https://doi.org/10.1007/s11864-022-00995-9>
4. Gao Y, Stein M, Kase M, Cummings AL, Bharanikumar R, Lau D, Garon EB, **Patel SP**. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer. *Cancer Immunology, Immunotherapy*. 2022/7/26

5. Chen R, Hakimi K, Zhang X, Messer K, **Patel SP**. Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer. *The Oncologist*. 2022/7/11
6. Hong DS, Gopal AK, Shoushtari AN, **Patel SP**... Fly KD, Ribas A. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. *Front. Immunol.*, 02 August 2022. Vol 13
7. Giustini NP, **Patel SP**...Wakelee H, Bazhenova L. Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. *JCO Precis Oncol.* Aug 6 2022.
8. Narunsky-Haziza L, Sepich-Poore GD, ... **Patel SP**, Bashan A, Swafford AD, Pilpel Y, Knight R, Straussman R. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. *Cell* 2022. Volume 185, Issue 20, 3789 - 3806.e17
9. McDaniels-Davidson C, Feng CH, Martinez ME... **Patel SP**, Mundt AJ, Mayadev JS. Improved survival in cervical cancer patients receiving care at National Cancer Institute–designated cancer centers. *Cancer* (128) 3479-3486 Oct 2022.
10. Bar J, Peled N, Schokrpur S... **Patel SP**, Gantz-Sorotsky H, Zer A, Moskovitz M, Metro, G, Rottenberg Y, Calles A, Hochmair M, Cuppens K, Decoster L, Reck M, Limon D, Rodrique E, Astaras C, Bettinni A, Hafliger S, Addeo A. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-Line Setting (UNICORN). *JTO* (18) 169-180. Feb 2023
11. Bendell J, LoRusso P, Overman M...Kumar R, **Patel SP**. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. *Cancer Immunology, Immunotherapy* 72, 2443-2458 (2023).
12. Kim DW, Kim SW, Camidge DR... **Patel SP**, Kar G, Cooper ZA, Samadani R, Pluta M, Kumar R, Ramalingam S. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. *JTO* (18) 650-656 May 2023.
13. Pagadala M, Sears TJ...**Patel SP**, Alexandrov LM, Mesirov JP, Zanetti M, Day CP, Fan C, Carter H. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response. *Nature Communications* (14) 12 May 2023.
14. Weitz J, Garg B, Martsinkovskiy A, **Patel SP**, Tiriach H, Lowy AM. Pancreatic ductal adenocarcinoma induces neural injury that promotes a transcriptomic and functional repair signature by peripheral neuroglia. *Oncogene* July 11 2023.
15. Negrao MV, Araujo HA, Lamberti G... **Patel SP**, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and

KRASG12C Inhibitor Efficacy in Advanced NSCLC. *Cancer Discovery* (2023) 13 (7) 1556-1571.

16. Nadal E, Saleh M, Aix SP, M, **Patel SP**, Antonia S, Zhao Y, Gueorguieva I, Man M, Estrem ST, Liu J, Avsar E, Lin WH, Benhadji KA, Gandhi L, Guba SC, Diaz IA. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. *BMC Cancer*. Article number: 708 (2023)
17. **Patel SP**, Othus M, Chae YK, Dennis MJ, ...Blanke C, Kurzrock R; A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. *Clin Cancer Res* 1 January 2024; 30 (1): 33–38. <https://doi.org/10.1158/1078-0432.CCR-23-2293>
18. **Patel SP**, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. *J Immunother Cancer*. 2024 Feb 2;12(2):e007340. doi: 10.1136/jitc-2023-007340. PMID: 38309722; PMCID: PMC10840023.
19. Othus M, **Patel SP**, Chae YK, ... Sharon E, Kurzrock R. Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial, *JNCI: Journal of the National Cancer Institute*, 2024;; djae009, <https://doi.org/10.1093/jnci/djae009>
20. **Patel SP**, Guadarrama E, Chae YK, et al. SWOG 1609 cohort 48: anti–CTLA-4 and anti–PD-1 for advanced gallbladder cancer. *Cancer*. 2024; 1-10. doi:10.1002/cncr.35243

Book Chapters

1. **Patel SP**, Kurzrock R. Early Phase Cancer Immunotherapy. 1st ed., Springer Verlag, 2018.
2. Schokrpur S, White MG, Roland CL, Patel SP. New Insights into Targets and Therapies. *Surgical Oncology Clinics*. Jan 8 2024. <https://doi.org/10.1016/j.soc.2023.12.006>